https://www.arvinas.com/publications/ 2026-04-09T14:49:28+00:00 https://www.arvinas.com/publication/effect-of-vepdegestrant-a-protac-oestrogen-receptor-degrader-on-dabigatran-and-rosuvastatin-pharmacokinetics-in-healthy-participants/ 2025-12-26T08:28:49+00:00 https://www.arvinas.com/publication/vepdegestrant-a-protac-estrogen-receptor-degrader-in-advanced-breast-cancer/ 2025-12-26T08:30:07+00:00 https://www.arvinas.com/publication/proteolysis-targeting-chimera-protac-estrogen-receptor-degraders-for-treatment-of-estrogen-receptor-positive-advanced-breast-cancer/ 2025-12-26T08:31:09+00:00 https://www.arvinas.com/publication/preclinical-evaluation-of-bavdegalutamide-arv-110-a-novel-proteolysis-targeting-chimera-androgen-receptor-degrader/ 2025-12-26T08:32:38+00:00 https://www.arvinas.com/publication/safety-and-pharmacokinetics-of-vepdegestrant-in-japanese-patients-with-er-advanced-breast-cancer-a-phase-1-study/ 2025-12-26T08:33:56+00:00 https://www.arvinas.com/publication/development-of-a-commercial-manufacturing-process-for-vepdegestrant-an-orally-bioavailable-protac-estrogen-receptor-degrader-for-the-treatment-of-breast-cancer/ 2025-12-26T08:35:10+00:00 https://www.arvinas.com/publication/new-therapies-on-the-horizon-targeted-protein-degradation-in-neuroscience/ 2025-12-26T08:36:58+00:00 https://www.arvinas.com/publication/veritac-2-a-phase-iii-study-of-vepdegestrant-a-protac-er-degrader-versus-fulvestrant-in-er-her2-advanced-breast-cancer/ 2025-12-26T08:38:48+00:00 https://www.arvinas.com/publication/oral-estrogen-receptor-protac-vepdegestrant-arv-471-is-highly-efficacious-as-monotherapy-and-in-combination-with-cdk4-6-or-pi3k-mtor-pathway-inhibitors-in-preclinical-er-breast-cancer-models/ 2025-12-26T08:40:09+00:00 https://www.arvinas.com/publication/systematic-literature-review-of-real-world-evidence-for-treatments-in-hr-her2-second-line-labc-mbc-after-first-line-treatment-with-cdk4-6i/ 2025-12-26T08:41:15+00:00 https://www.arvinas.com/publication/protacs-targeting-brm-smarca2-afford-selective-in-vivo-degradation-over-brg1-smarca4-and-are-active-in-brg1-mutant-xenograft-tumor-models/ 2025-12-26T08:42:36+00:00 https://www.arvinas.com/publication/co-opting-the-e3-ligase-klhdc2-for-targeted-protein-degradation-by-small-molecules/ 2025-12-26T08:44:09+00:00 https://www.arvinas.com/publication/physicochemical-property-determinants-of-oral-absorption-for-protac-protein-degraders/ 2025-12-26T08:45:24+00:00 https://www.arvinas.com/publication/protein-degraders-enter-the-clinic-a-new-approach-to-cancer-therapy/ 2025-12-26T08:46:31+00:00 https://www.arvinas.com/publication/dna-encoded-library-del-selection-identifies-a-distinct-ddb1-ligand-binding-site/ 2026-04-01T06:46:25+00:00 https://www.arvinas.com/publication/protac-targeted-protein-degraders-the-past-is-prologue/ 2026-04-09T14:49:28+00:00